TuftsCSDD-Logo-Color.jpg
Innovation in Drug Development Process Remains a Key Challenge, Tufts Center for the Study of Drug Development Says
October 20, 2015 09:00 ET | Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwired - Oct 20, 2015) - Although pharmaceutical companies have long aspired to improve drug development efficiency, the drug development process remains highly inefficient and...
TuftsCSDD-Logo-Color.jpg
Adverse Drug Event Reporting in U.S. Beset by Incompleteness and Inaccuracy, According to the Tufts Center for the Study of Drug Development
September 16, 2015 09:00 ET | Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwired - Sep 16, 2015) - Voluntary adverse drug event (ADE) reporting in the United States is incomplete, inaccurate, and inefficient, which could deny or limit patient access to...
TuftsCSDD-Logo-Color.jpg
Personalized Medicine Development Tied to Showing Value of Companion Diagnostics, Tufts Center for the Study of Drug Development Says
August 19, 2015 09:00 ET | Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwired - Aug 19, 2015) - With interest in personalized medicines growing, drug and diagnostics companies are investing in the development of companion diagnostics that can show...
TuftsCSDD-Logo-Color.jpg
Vaccine Products in Development Have Tripled Over Last Decade, Tufts Center for the Study of Drug Development Study Says
July 09, 2015 09:00 ET | Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwired - Jul 9, 2015) - Vaccine products in the R&D pipeline have more than tripled since 2005 and annual worldwide sales are on track to reach $40 billion by 2020, according...
TuftsCSDD-Logo-Color.jpg
Personalized Medicine Is Gaining Traction, but Faces Multiple Challenges, Tufts Center for the Study of Drug Development Study Concludes
May 14, 2015 09:00 ET | Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwired - May 14, 2015) - While development of personalized medicines has grown since the human genome was first sequenced in 2001, biopharmaceutical sponsors face a number of...
TuftsCSDD-Logo-Color.jpg
Biopharma Summit Set for May 12 on Re-Engineering Clinical Trials to Improve Drug Development and Performance
April 21, 2015 09:00 ET | Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwired - Apr 21, 2015) - Responding to the mounting challenges of highly inefficient and costly clinical trials, which have stymied R&D productivity, the Tufts Center for the...
TuftsCSDD-Logo-Color.jpg
Early BTD Projects Offer Lessons for Drug Companies, Tufts Center for the Study of Drug Development Says
April 14, 2015 09:00 ET | Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwired - Apr 14, 2015) -  Flexibility and a willingness to learn from each other are key factors that enable drug companies and regulators to engage successfully in...
TuftsCSDD-Logo-Color.jpg
U.S. Biosimilar Approvals Poised to Grow, but Market Uptake Faces Several Challenges, According to the Tufts Center for the Study of Drug Development
March 05, 2015 09:00 ET | Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwired - Mar 5, 2015) - Biosimilar approvals in the United States are expected to increase during the next five years, but safety concerns among physicians and the need for...
TuftsCSDD-Logo-Color.jpg
Sponsors and CROs Implementing New Ways to Better Leverage Investigative Site Relationships, According to the Tufts Center for the Study of Drug Development
January 29, 2015 09:00 ET | Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwired - Jan 29, 2015) - Improved investigative site relationship use and effectiveness are top objectives in 2015 for pharmaceutical companies and contract research...
TuftsCSDD-Logo-Color.jpg
High Turnover and Protocol Noncompliance Continue to Plague the Global Investigative Site Landscape, According to the Tufts Center for the Study of Drug Development
January 15, 2015 09:00 ET | Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwired - Jan 15, 2015) - Global clinical trial performance and efficiency are hampered by high turnover and noncompliance among principal investigators and wide variation in...